Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up-Reference-Cited by-同舟云学术

Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up

Published:1993-10 Issue:5 Volume:13 Page:333-340
ISSN:0197-8357
Container-title:Journal of Interferon Research
language:en
Short-container-title:Journal of Interferon Research

Author:

KNOBLER R.L.,GREENSTEIN J.I.,JOHNSON K.P.,LUBLIN F.D.,PANITCH H.S.,CONWAY K.,GRANT-GORSEN S.V.,MULDOON J.,MARCUS S.G.,WALLENBERG J.C.,WILLIAMS G.J.,YOSHIZAWA C.N.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jir.1993.13.333

Reference19 articles.

1. Multiple Sclerosis

2. Systemic alpha-interferon therapy of multiple sclerosis

3. Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

4. Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation;Autoimmunity Reviews;2024-02

2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

3. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

4. Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development – ( III ) A Randomized Trial with Interferon Beta‐1a Products;Clinical Pharmacology & Therapeutics;2022-12-02

5. Do Hungarian multiple sclerosis care units fulfil international criteria?;PLOS ONE;2022-03-03